Name
AGALSIDASE BETA
Mode of Action
ALPHA GALACTOSIDASE A IS AN ENDOGENOUS ENZYME THAT HYDROLYSES TERMINAL ?-D-GALACTOSE RESIDUES IN OLIGOSACCHARIDES AND GALACTOLIPIDS INTO MORE EASILY DIGESTIBLE MONO- AND DISACCHARIDES. A FORM DERIVED FROM A FUNGAL SOURCE IS USED TO PREVENT INTESTINAL GAS. AGALSIDASE ALFA AND BETA ARE RECOMBINANT FORMS OF ALPHA GALACTOSIDASE A USED FOR THE LONG-TERM ENZYME REPLACEMENT THERAPY OF FABRY DISEASE .
Dosage
1.0 MG /KG BODY WT INFUSED IV EVERY 2 WEEKS. PT SHOULD RECEIVE ANTIPYRETIC BEFORE INJECTION AGALSIDASE BETA IS GIVEN BY INTRAVENOUS INFUSION IN A DOSE OF 1 MG/KG AT AN INITIAL RATE OF NO MORE THAN 250 MICROGRAMS/MINUTE; THE RATE MAY BE GRADUALLY INCREASED (BY 5 TO 8 MICROGRAMS/MINUTE IN EACH SUBSEQUENT INFUSION) ONCE TOLERANCE HAS BEEN ESTABLISHED. THE DOSE SHOULD BE REPEATED EVERY ALTERNATE WEEK.
Drug Group
[ENZYME] , [RECOMBINANT FORM OF ALFA GALACTOSIDASE A ENZYME]
Cross Reaction
AGALSIDASE ALFA OR BETA SHOULD NOT BE USED WITH AMIODARONE, CHLOROQUINE, MONOBENZONE, OR GENTAMICIN, WHICH ALL HAVE THE POTENTIAL TO INHIBIT INTRACELLULAR ?-GALACTOSIDASE ACTIVITY.
Drug Interaction
Drugs Side Effect
Drug Categories
Special Precaution
Drug Safety
Monograph